Literature DB >> 11566347

A unique AML1 (CBF2A) rearrangement, t(1;21)(p32;q22), observed in a patient with acute myelomonocytic leukemia.

A M Cherry1, C D Bangs, P Jones, S Hall, Y Natkunam.   

Abstract

The AML1 (CBFA2) gene is the most frequent target of chromosomal rearrangements observed in human acute leukemia. These rearrangements include the commonly reported t(8;21)(q22;q22) or AML1/ETO fusion in AML-M2, the t(3;21)(q26;q22) or AML1 fusion with one of three genes, MDS1, EAP or EVI1, in therapy-related AML and MDS, as well as in blast crisis in CML and the t(12;21)(p13;q22) or TEL/AML1 fusion in B-cell ALL. In addition to the t(3;21), other AML1 translocations have also been reported in therapy-related MDS and AML, particularly after treatment with topoisomerase II inhibitors. AML1 gene rearrangements have also been observed less frequently with numerous other chromosomal partners. Here, we describe a patient with AML-M4 and a previously unreported rearrangement involving the AML1 locus and an unknown locus on the short arm of chromosome 1 at 1p32.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11566347     DOI: 10.1016/s0165-4608(01)00439-3

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  3 in total

1.  Truncated RUNX1 protein generated by a novel t(1;21)(p32;q22) chromosomal translocation impairs the proliferation and differentiation of human hematopoietic progenitors.

Authors:  S Rodriguez-Perales; R Torres-Ruiz; J Suela; F Acquadro; M C Martin; E Yebra; J C Ramirez; S Alvarez; J C Cigudosa
Journal:  Oncogene       Date:  2015-03-23       Impact factor: 9.867

2.  Genome-wide mapping and characterization of hypomethylated sites in human tissues and breast cancer cell lines.

Authors:  Yih-Jyh Shann; Ching Cheng; Chun-Hui Chiao; Dow-Tien Chen; Pei-Hsin Li; Ming-Ta Hsu
Journal:  Genome Res       Date:  2008-02-06       Impact factor: 9.043

3.  Additional acquisition of t(1;21)(p32;q22) in a patient relapsing with acute myelogenous leukemia with NUP98-HOXA9.

Authors:  Takatoshi Aoki; Toshihiro Miyamoto; Shuro Yoshida; Asataro Yamamoto; Takuji Yamauchi; Goichi Yoshimoto; Yasuo Mori; Kenjiro Kamezaki; Hiromi Iwasaki; Katsuto Takenaka; Naoki Harada; Koji Nagafuji; Takanori Teshima; Koichi Akashi
Journal:  Int J Hematol       Date:  2008-11-13       Impact factor: 2.490

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.